Earnings Call Summary | Aethlon Medical(AEMD.US) Q3 2024 Earnings Conference
Earnings Call Summary | Aethlon Medical(AEMD.US) Q3 2024 Earnings Conference
The following is a summary of the Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript:
以下是 Aethlon Medical, Inc. (AEMD) 2024 年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Aethlon Medical had a cash balance of approximately $8 million as of December 31, 2023, and raised approximately $236,000 through common stock sales.
Consolidated operating expenses for the 3 months ending December 31, 2023, were about $3.6 million, up from $2.8 million in the same period the previous year.
The company saw a net loss increase to $3.6 million for the 3 months ending December 31, 2023, from $2.8 million in the same period the previous year.
截至2023年12月31日，Aethlon Medical的現金餘額約爲800萬美元，通過普通股銷售籌集了約23.6萬美元。
截至2023年12月31日的3個月的合併運營支出約爲360萬美元，高於去年同期的280萬美元。
截至2023年12月31日的3個月中，該公司的淨虧損從去年同期的280萬美元增至360萬美元。
Business Progress:
業務進展：
Aethlon Medical received clearance to conduct a Phase I trial for the Hemopurifier from the Drug Controller General of India and is set to begin following an in vitro binding study.
The company is exploring the use of Hemopurifier against viral infections through a COVID-19 trial in India.
Aethlon Medical is finalizing essentials for initiating oncology studies in India and Australia.
Aethlon Medical獲得了印度藥品監督局對血液淨化劑進行I期試驗的許可，並將在體外結合研究後開始。
該公司正在印度通過一項 COVID-19 試驗，探索使用血液淨化劑來對抗病毒感染。
Aethlon Medical正在敲定在印度和澳大利亞啓動腫瘤學研究的基本要素。
More details: Aethlon Medical IR
更多詳情： Aethlon Medical IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。